Orthopediatrics Corp ( (KIDS) ) has released its Q1 earnings. Here is a breakdown of the information Orthopediatrics Corp presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
OrthoPediatrics Corp., a company dedicated to pediatric orthopedics, has reported its financial results for the first quarter of 2025, showcasing significant growth and strategic advancements in its operations.
The company achieved a 17% increase in revenue year-over-year, reaching $52.4 million, with notable growth in both domestic and international markets. The launch of the VerteGlide System for Early Onset Scoliosis and increased revenue from Trauma & Deformity and Scoliosis segments contributed to this strong performance.
Despite a net loss of $10.7 million, OrthoPediatrics improved its adjusted EBITDA to a loss of $0.4 million from $1.1 million in the previous year. The company also reduced its free cash flow usage by 35% and anticipates positive free cash flow by the fourth quarter of 2025. Operating expenses rose due to increased personnel and stock compensation, reflecting the company’s ongoing expansion efforts.
Looking ahead, OrthoPediatrics has increased its full-year 2025 revenue guidance, projecting growth between 15% and 18%. The company’s strategic focus on scaling operations and launching innovative products positions it well for continued growth in the pediatric orthopedic market.